Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Experimental Hematology & Oncology

Kristina Drott³  Anne Hultquist⁴  Urban Gullberg³  Mats Jerkeman²  Mats Ehinger¹  Sandra Gordon³  Jesper Kofoed Damm³ 

[1] Department of Pathology, Skåne University Hospital, Lund, Sweden;Department of Oncology, Skåne University Hospital, Lund, Sweden;Department of Hematology and Transfusion Medicine, Lund University, Lund, Sweden;Stem Cell Center (SCC), Lund University, Lund, Sweden

关键词: HDACi;    Rituximab;    DLBCL;    CD20;    Valproic acid;    Valproate;   

Others  :  1135260
DOI  :  10.1186/2162-3619-4-4

实施日期：2015-01-17，发布日期：2015-01-26

【 摘 要 】

Background

Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.

Findings

Pretreatment with valproate at oral doses comparable to anti-convulsive therapy, resulted in upregulation of CD20 mRNA and CD20 protein on the cell surface as measured by qPCR and FACS analysis in lymphoma biopsies from three evaluated patients from the VALFRID study. Valproate-treatment corresponded to increased acetylation of Histone3Lysine9 (H3K9ac) in peripheral blood mononuclear cells (PBMCs), which were employed as surrogate tissue for valproate-related epigenetic modifications.

Conclusions

Valproate treatment at pharmacologically relevant doses resulted in upregulation of CD20 in vivo, and also in expected epigenetic modifications. This suggests that pre-treatment with valproate or other HDACis before anti-CD20 therapy could be advantageous in CD20-low B-cell lymphomas. Further studies are warranted to evaluate this conclusion.

【 授权许可】

   
2015 Damm et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al.: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
• [2]Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al.: Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
• [3]Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al.: Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830-837.
• [4]Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, et al.: Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010, 151:143-151.
• [5]Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, et al.: Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009, 390:48-53.
• [6]Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS: Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012, 18:1039-1050.
• [7]Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y: HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010, 24:1760-1768.
• [8]Chateauvieux S, Morceau F, Dicato M, Diederich M: Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010., 2010
• [9]Ageberg M, Rydstrom K, Linden O, Linderoth J, Jerkeman M, Drott K: Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Exp Cell Res 2011, 317:1179-1191.
• [10]Lund University Hospital: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (VALFRID). ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2014 Jun 3]Available from: http://clinicaltrials.gov/show/NCT01622439 webcite NLM Identifier: NCT01622439
• [11]Medical Products Agency of Sweden - FASS Drug Database: Medical Products Agency of Sweden - FASS Drug Database. http://www.fass.se/LIF/product?userType=2&nplid=19951020000076 webcite
• [12]Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, et al.: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009, 15:2488-2496.
• [13]Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM: Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 2007, 282:4408-4416.
• [14]Paino F, La Noce M, Tirino V, Naddeo P, Desiderio V, Pirozzi G, et al.: Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells 2014, 32:279-289.
• [15]Yang FQ, Liu M, Yang FP, Che J, Li W, Zhai W, et al.: VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1alpha. Mol Biol Rep 2014, 41:1511-1518.
• [16]James DF, Kipps TJ: Rituximab in chronic lymphocytic leukemia. Adv Ther 2011, 28:534-554.
• [17]Lund University Hospital: Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia (PREVAIL). ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2014 Jun 3]Available from: http://clinicaltrials.gov/show/NCT02144623 webcite NLM Identifier: NCT02144623